دورية أكاديمية
أعرض في EDS

Components of the metabolic syndrome in girls with Turner syndrome treated with growth hormone in a long term prospective study.

التفاصيل البيبلوغرافية
العنوان: Components of the metabolic syndrome in girls with Turner syndrome treated with growth hormone in a long term prospective study.
المؤلفون: Błaszczyk E; Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland., Shulhai AM; Department of Pediatrics N°2, Ivan Horbachevsky Ternopil National Medical University, Ternopil, Ukraine., Gieburowska J; Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland., Barański K; Department of Epidemiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland., Gawlik AM; Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
المصدر: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Jul 11; Vol. 14, pp. 1216464. Date of Electronic Publication: 2023 Jul 11 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Human Growth Hormone*/therapeutic use , Insulin Resistance* , Metabolic Syndrome*/complications , Metabolic Syndrome*/drug therapy , Turner Syndrome*/complications , Turner Syndrome*/drug therapy, Humans ; Cholesterol ; Glucose/metabolism ; Growth Hormone/therapeutic use ; Insulin ; Prospective Studies
مستخلص: Background: Components of the metabolic syndrome are more common in patients with Turner syndrome (TS) than in the general population. Long-term growth hormone (GH) treatment also affects the parameters of carbohydrate metabolism. Therefore, all these factors should be monitored in girls with TS.
Objective: To assess the occurrence of metabolic syndrome components in TS girls before GH treatment and to monitor changes in metabolic parameters throughout GH therapy.
Patients and Method: 89 TS patients were enrolled in the study. Clinical and laboratory data after the 1st (V1), 3rd (V3), 5th (V5) and 10th (V10) year of GH therapy was available respectively in 60, 76, 50 and 22 patients. The patients' biochemical phenotypes were determined by glucose 0', 120', insulin 0', 120', HOMA-IR, Ins/Glu ratio, HDL-cholesterol and triglycerides (TG) concentration.
Results: Obesity was found during V0 in 7.9% of patients,V1 - 5%, V3 - 3.9%, V5 - 2%, V10 - 0%. No patient met diagnostic criteria for diabetes. A significant increase in the basal plasma glucose 0' was found in the first five years of therapy (pV0-V1 < 0.001; pV0-V3 = 0.006; pV0-V5 < 0.001). V10 glucose 120' values were significantly lower than at the onset of GH treatment (pV0-V10 = 0.046). The serum insulin 0' and 120' concentrations as well as insulin resistance increased during treatment. No statistically significant differences in serum TG and HDL-cholesterol levels during GH therapy were found.
Conclusion: The development of insulin resistance and carbohydrate metabolism impairment have the greatest manifestations during GH therapy in girls with TS. Monitoring the basic parameters of carbohydrate-lipid metabolism in girls with TS seems particularly important.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Błaszczyk, Shulhai, Gieburowska, Barański and Gawlik.)
References: Int J Pediatr Endocrinol. 2012 Apr 02;2012(1):5. (PMID: 22472028)
Clin Endocrinol (Oxf). 1996 Nov;45(5):589-93. (PMID: 8977756)
Arch Dis Child. 1969 Jun;44(235):291-303. (PMID: 5785179)
Orphanet J Rare Dis. 2022 Jul 12;17(Suppl 1):261. (PMID: 35821070)
Circulation. 2003 Sep 30;108(13):1546-51. (PMID: 14517150)
J Clin Endocrinol Metab. 2006 May;91(5):1785-8. (PMID: 16507631)
J Clin Endocrinol Metab. 2005 May;90(5):2631-5. (PMID: 15713713)
Eur J Pediatr. 2000 Jan-Feb;159(1-2):91-4. (PMID: 10653338)
Pediatr Diabetes. 2003 Sep;4(3):119-25. (PMID: 14655269)
Horm Res. 2001;55(5):240-4. (PMID: 11740146)
Int J Obes (Lond). 2014 Sep;38 Suppl 2:S4-14. (PMID: 25376220)
BMC Endocr Disord. 2011 Mar 15;11:6. (PMID: 21406078)
N Engl J Med. 2004 Sep 16;351(12):1227-38. (PMID: 15371580)
J Clin Endocrinol Metab. 2006 Oct;91(10):3897-902. (PMID: 16849410)
Eur J Endocrinol. 2004 Sep;151(3):351-4. (PMID: 15362964)
Curr Opin Pediatr. 2022 Aug 1;34(4):447-460. (PMID: 35796656)
J Clin Res Pediatr Endocrinol. 2015 Mar;7(1):27-36. (PMID: 25800473)
J Clin Endocrinol Metab. 2008 Jun;93(6):2109-14. (PMID: 18349057)
Curr Diab Rep. 2016 Jul;16(7):64. (PMID: 27179965)
Hypertension. 2016 Jul;68(1):133-6. (PMID: 27217413)
Endocr Rev. 2008 Dec;29(7):777-822. (PMID: 18971485)
Int J Obes (Lond). 2007 Apr;31(4):591-600. (PMID: 17384660)
J Clin Endocrinol Metab. 2006 Nov;91(11):4302-5. (PMID: 16940444)
Horm Res Paediatr. 2012;77(4):222-8. (PMID: 22538845)
Lancet. 2010 Jul 10;376(9735):112-23. (PMID: 20561675)
Eur J Endocrinol. 2017 Sep;177(3):G1-G70. (PMID: 28705803)
Adv Pediatr. 2022 Aug;69(1):177-202. (PMID: 35985709)
JAMA. 2007 Jan 17;297(3):286-94. (PMID: 17227980)
J Clin Endocrinol Metab. 2002 Dec;87(12):5442-8. (PMID: 12466334)
Horm Res. 2007;68(1):1-7. (PMID: 17204837)
J Pediatr Endocrinol Metab. 2020 Nov 26;33(11):1363-1372. (PMID: 33151179)
Clin Endocrinol (Oxf). 2013 Jun;78(6):907-13. (PMID: 23106295)
Diabetes Care. 1998 Jul;21(7):1062-70. (PMID: 9653596)
J Clin Epidemiol. 1998 Feb;51(2):147-58. (PMID: 9474075)
J Clin Endocrinol Metab. 2000 Feb;85(2):769-75. (PMID: 10690889)
J Clin Endocrinol Metab. 2019 Feb 1;104(2):379-389. (PMID: 30219920)
Front Endocrinol (Lausanne). 2019 Feb 07;10:49. (PMID: 30792694)
Front Endocrinol (Lausanne). 2018 Oct 16;9:609. (PMID: 30459711)
J Clin Endocrinol Metab. 2001 Jul;86(7):3061-9. (PMID: 11443168)
J Clin Endocrinol Metab. 1991 Apr;72(4):832-6. (PMID: 2005209)
Lancet. 2007 Jun 23;369(9579):2059-61. (PMID: 17586288)
Pediatrics. 2005 Mar;115(3):732-5. (PMID: 15741379)
J Clin Res Pediatr Endocrinol. 2008;1(2):62-71. (PMID: 21318066)
Arch Dis Child. 2005 Jan;90(1):10-4. (PMID: 15613503)
Horm Res. 2009;71(6):343-9. (PMID: 19506392)
Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7. (PMID: 12912790)
Clin Endocrinol (Oxf). 1998 Oct;49(4):447-50. (PMID: 9876341)
J Clin Endocrinol Metab. 2004 Jul;89(7):3516-20. (PMID: 15240640)
Clin Cardiol. 2005 Feb;28(2):88-92. (PMID: 15757080)
Pediatr Obes. 2012 Aug;7(4):284-94. (PMID: 22715120)
J Endocrinol Invest. 2022 Dec;45(12):2247-2256. (PMID: 35907176)
فهرسة مساهمة: Keywords: glucose homeostasis; growth hormone therapy; insulin resistance/hyperinsulinemia; lipids; metabolic syndrome; obesity; turner syndrome
المشرفين على المادة: 97C5T2UQ7J (Cholesterol)
IY9XDZ35W2 (Glucose)
9002-72-6 (Growth Hormone)
12629-01-5 (Human Growth Hormone)
0 (Insulin)
تواريخ الأحداث: Date Created: 20230727 Date Completed: 20230803 Latest Revision: 20230803
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10367090
DOI: 10.3389/fendo.2023.1216464
PMID: 37497348
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-2392
DOI:10.3389/fendo.2023.1216464